Skip Nav Destination
Issues
1 October 2013
-
Cover Image
Cover Image
This image shows H3K9 trimethylation (H3K9me3) of nuclear histone proteins as a marker for cellular senescence. Immunofluorescence picture of HepG2 human hepatoblastoma cells treated with 20 μmol/L 5-aza-2′-deoxycytidine (5-aza-dC, Dacogen) for a 72-hour time period. Cells were stained using DAPI, α-tubulin, and α-trimethylation of H3K9 (histone protein H3K9me3). The green spots within the cellular nucelus represent the presence of the senescence marker H3K9me3 as a cellular response to the treatment with the DNA-methyltransferase inhibitor 5-aza-2′-deoxycytidine. For more details, see the article by Venturelli and colleagues on page 2226. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance
Christine Haider; Markus Grubinger; Eva Řezníčková; Thomas S. Weiss; Hans Rotheneder; Walter Miklos; Walter Berger; Radek Jorda; Marek Zatloukal; Tomáš Gucký; Miroslav Strnad; Vladimír Kryštof; Wolfgang Mikulits
Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Elizabeth Blackwood; Jennifer Epler; Ivana Yen; Michael Flagella; Tom O'Brien; Marie Evangelista; Stephen Schmidt; Yang Xiao; Jonathan Choi; Kaska Kowanetz; Judi Ramiscal; Kenton Wong; Diana Jakubiak; Sharon Yee; Gary Cain; Lewis Gazzard; Karen Williams; Jason Halladay; Peter K. Jackson; Shiva Malek
A Urokinase Receptor–Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting
Katia Bifulco; Immacolata Longanesi-Cattani; Eleonora Liguori; Claudio Arra; Domenica Rea; Maria Teresa Masucci; Mario De Rosa; Vincenzo Pavone; Maria Patrizia Stoppelli; Maria Vincenza Carriero
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Ryan T. Anderson; Stephen B. Keysar; Daniel W. Bowles; Magdalena J. Glogowska; David P. Astling; J. Jason Morton; Phuong Le; Adrian Umpierrez; Justin Eagles-Soukup; Gregory N. Gan; Brian W. Vogler; Daniel Sehrt; Sarah M. Takimoto; Dara L. Aisner; Francois Wilhelm; Barbara A. Frederick; Marileila Varella-Garcia; Aik-Choon Tan; Antonio Jimeno
Large Molecule Therapeutics
Author Choice
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter; Frank Herting; Olaf Mundigl; Inja Waldhauer; Tina Weinzierl; Tanja Fauti; Gunter Muth; Doris Ziegler-Landesberger; Erwin Van Puijenbroek; Sabine Lang; Minh Ngoc Duong; Lina Reslan; Christian A. Gerdes; Thomas Friess; Ute Baer; Helmut Burtscher; Michael Weidner; Charles Dumontet; Pablo Umana; Gerhard Niederfellner; Marina Bacac; Christian Klein
Cancer Therapeutics Insights
Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca2+/Calmodulin-Dependent Protein Kinase II
Zhipeng Meng; Tao Li; Xiaoxiao Ma; Xiaoqiong Wang; Carl Van Ness; Yichao Gan; Hong Zhou; Jinfen Tang; Guiyu Lou; Yafan Wang; Jun Wu; Yun Yen; Rongzhen Xu; Wendong Huang
Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers
Erik A. Bey; Kathryn E. Reinicke; Melissa C. Srougi; Marie Varnes; Vernon E. Anderson; John J. Pink; Long Shan Li; Malina Patel; Lifen Cao; Zachary Moore; Amy Rommel; Michael Boatman; Cheryl Lewis; David M. Euhus; William G. Bornmann; Donald J. Buchsbaum; Douglas R. Spitz; Jinming Gao; David A. Boothman
Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump
Thibault Mazard; Annick Causse; Joelle Simony; Wilhem Leconet; Nadia Vezzio-Vie; Adeline Torro; Marta Jarlier; Alexandre Evrard; Maguy Del Rio; Eric Assenat; Pierre Martineau; Marc Ychou; Bruno Robert; Celine Gongora
Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations
Jennifer J. Wheler; Apostolia M. Tsimberidou; Gerald S. Falchook; Ralph G. Zinner; David S. Hong; Jansina Y. Fok; Siqing Fu; Sarina A. Piha-Paul; Aung Naing; Razelle Kurzrock
EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas
Devraj Basu; Arnaud F. Bewley; Steven M. Sperry; Kathleen T. Montone; Phyllis A. Gimotty; Kati Rasanen; Nicole D. Facompre; Gregory S. Weinstein; Hiroshi Nakagawa; J. Alan Diehl; Anil K. Rustgi; Meenhard Herlyn
Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2′-Deoxycytidine in Solid Tumor Cells
Sascha Venturelli; Alexander Berger; Timo Weiland; Frank Essmann; Michaela Waibel; Tina Nuebling; Sabine Häcker; Martin Schenk; Klaus Schulze-Osthoff; Helmut R. Salih; Simone Fulda; Bence Sipos; Ricky W. Johnstone; Ulrich M. Lauer; Michael Bitzer
Companion Diagnostics and Biomarkers
Author Choice
Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States
Takeru Wakatsuki; Melissa J. LaBonte; Pierre O. Bohanes; Wu Zhang; Dongyun Yang; Mizutomo Azuma; Afsaneh Barzi; Yan Ning; Fotios Loupakis; Siamak Saadat; Nico Volz; Sebastian Stintzing; Rita El-Khoueiry; Wasaburo Koizumi; Masahiko Watanabe; Manish Shah; Justin Stebbing; Georgios Giamas; Heinz-Josef Lenz
Tools and Technologies
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.